Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 665

1.

Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing.

Streubel A, Stenzinger A, Stephan-Falkenau S, Kollmeier J, Misch D, Blum TG, Bauer T, Landt O, Am Ende A, Schirmacher P, Mairinger T, Endris V.

Oncotarget. 2019 Oct 1;10(55):5690-5702. doi: 10.18632/oncotarget.27183. eCollection 2019 Oct 1.

PMID:
31620244
2.

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.

Cancer Immunol Immunother. 2019 Sep 23. doi: 10.1007/s00262-019-02393-x. [Epub ahead of print]

PMID:
31549213
3.

Plasma metabolites associated with colorectal cancer stage: Findings from an international consortium.

Geijsen AJMR, van Roekel EH, van Duijnhoven FJB, Achaintre D, Bachleitner-Hofmann T, Baierl A, Bergmann MM, Boehm J, Bours MJL, Brenner H, Breukink SO, Brezina S, Chang-Claude J, Herpel E, de Wilt JHW, Gicquiau A, Gigic B, Gumpenberger T, Hansson BME, Hoffmeister M, Holowatyj AN, Karner-Hanusch J, Keski-Rahkonen P, Keulen ETP, Koole JL, Leeb G, Ose J, Schirmacher P, Schneider MA, Schrotz-King P, Stift A, Ulvik A, Vogelaar FJ, Wesselink E, van Zutphen M, Gsur A, Habermann N, Kampman E, Scalbert A, Ueland PM, Ulrich AB, Ulrich CM, Weijenberg MP, Kok DE.

Int J Cancer. 2019 Sep 8. doi: 10.1002/ijc.32666. [Epub ahead of print]

PMID:
31495913
4.

RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples.

Kirchner M, Neumann O, Volckmar AL, Stögbauer F, Allgäuer M, Kazdal D, Budczies J, Rempel E, Brandt R, Talla SB, von Winterfeld M, Leichsenring J, Bochtler T, Krämer A, Springfeld C, Schirmacher P, Penzel R, Endris V, Stenzinger A.

Cancers (Basel). 2019 Sep 5;11(9). pii: E1309. doi: 10.3390/cancers11091309.

5.

Association between serum IgG level and clinical course in primary sclerosing cholangitis.

Hippchen T, Sauer P, Göppert B, Schirmacher P, Gotthardt DN, Weiss KH, Stremmel W, Rupp C.

BMC Gastroenterol. 2019 Aug 27;19(1):153. doi: 10.1186/s12876-019-1075-0.

6.

Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer.

Badr M, Jöhrens K, Allgäuer M, Boxberg M, Weichert W, Tinhofer I, Denkert C, Schirmacher P, Stenzinger A, Budczies J.

Cancer Immunol Immunother. 2019 Sep;68(9):1443-1454. doi: 10.1007/s00262-019-02378-w. Epub 2019 Aug 23.

PMID:
31444607
7.

The 2019 WHO classification of tumours of the digestive system.

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington MK, Carneiro F, Cree IA.

Histopathology. 2019 Aug 21. doi: 10.1111/his.13975. [Epub ahead of print]

PMID:
31433515
8.

Molecular characterization of hepatic epithelioid hemangioendothelioma reveals alterations in various genes involved in DNA repair, epigenetic regulation, signaling pathways, and cell cycle control.

Mogler C, Koschny R, Heilig CE, Frohling S, Schirmacher P, Weichert W, Pfarr N.

Genes Chromosomes Cancer. 2019 Aug 7. doi: 10.1002/gcc.22795. [Epub ahead of print]

PMID:
31390105
9.

Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.

Kazdal D, Endris V, Allgäuer M, Kriegsmann M, Leichsenring J, Volckmar AL, Harms A, Kirchner M, Kriegsmann K, Neumann O, Brandt R, Talla SB, Rempel E, Ploeger C, von Winterfeld M, Christopoulos P, Merino DM, Stewart M, Allen J, Bischoff H, Meister M, Muley T, Herth F, Penzel R, Warth A, Winter H, Fröhling S, Peters S, Swanton C, Thomas M, Schirmacher P, Budczies J, Stenzinger A.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30563-5. doi: 10.1016/j.jtho.2019.07.006. [Epub ahead of print]

PMID:
31349062
10.

Optimizing panel-based tumor mutational burden (TMB) measurement.

Budczies J, Allgäuer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D, Endris V, Thomas M, Fröhling S, Peters S, Swanton C, Schirmacher P, Stenzinger A.

Ann Oncol. 2019 Sep 1;30(9):1496-1506. doi: 10.1093/annonc/mdz205.

PMID:
31268125
11.

Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.

Schwamborn K, Ammann JU, Knüchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, Braunschweig T, Tauber R, Erlmeier F, Hieke-Schulz S, Weichert W.

Virchows Arch. 2019 Jul 2. doi: 10.1007/s00428-019-02610-z. [Epub ahead of print]

PMID:
31267201
12.

Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer.

Haffa M, Holowatyj AN, Kratz M, Toth R, Benner A, Gigic B, Habermann N, Schrotz-King P, Böhm J, Brenner H, Schneider M, Ulrich A, Herpel E, Schirmacher P, Straub BK, Nattenmüller J, Kauczor HU, Lin T, Ball CR, Ulrich CM, Glimm H, Scherer D.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5225-5237. doi: 10.1210/jc.2019-00461.

PMID:
31225875
13.

Perilipin 1 Expression Differentiates Liposarcoma from Other Types of Soft Tissue Sarcoma.

Straub BK, Witzel HR, Pawella LM, Renner M, Eiteneuer E, Hashani M, Schirmacher P, Roth W, Mechtersheimer G.

Am J Pathol. 2019 Aug;189(8):1547-1558. doi: 10.1016/j.ajpath.2019.04.017. Epub 2019 May 22.

PMID:
31125552
14.

[From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?]

Leichsenring J, Kazdal D, Ploeger C, Allgäuer M, Endris V, Volckmar AL, Neumann O, Kirchner M, Penzel R, Rempel E, Budczies J, Schirmacher P, Fröhling S, Stenzinger A.

Pathologe. 2019 May;40(3):235-242. doi: 10.1007/s00292-019-0608-1. German.

PMID:
31089797
15.

Nucleoporin Nup155 is part of the p53 network in liver cancer.

Holzer K, Ori A, Cooke A, Dauch D, Drucker E, Riemenschneider P, Andres-Pons A, DiGuilio AL, Mackmull MT, Baßler J, Roessler S, Breuhahn K, Zender L, Glavy JS, Dombrowski F, Hurt E, Schirmacher P, Beck M, Singer S.

Nat Commun. 2019 May 14;10(1):2147. doi: 10.1038/s41467-019-10133-z.

16.

Low frequency of mismatch repair deficiency in gallbladder cancer.

Goeppert B, Roessler S, Renner M, Loeffler M, Singer S, Rausch M, Albrecht T, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M.

Diagn Pathol. 2019 May 8;14(1):36. doi: 10.1186/s13000-019-0813-5.

17.

Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.

Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, Thewes V, Lichter P, Schirmacher P, Kloor M, Marmé F, Schütz F, Kosaloglu Z, Sinn HP, Jäger D, Schneeweiss A.

Breast Care (Basel). 2019 Mar;14(1):53-59. doi: 10.1159/000492580. Epub 2018 Nov 14.

PMID:
31019444
18.

Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network.

Pfarr N, Allgäuer M, Steiger K, Weichert W, Schirmacher P, Noske A, Stenzinger A.

Pathology. 2019 Jun;51(4):362-368. doi: 10.1016/j.pathol.2019.01.010. Epub 2019 Apr 19.

PMID:
31010589
19.

Variant classification in precision oncology.

Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, Neumann O, Kirchner M, Ploeger C, Budczies J, Heilig CE, Hutter B, Fröhlich M, Uhrig S, Kazdal D, Allgäuer M, Harms A, Rempel E, Lehmann U, Thomas M, Pfarr N, Azoitei N, Bonzheim I, Marienfeld R, Möller P, Werner M, Fend F, Boerries M, von Bubnoff N, Lassmann S, Longerich T, Bitzer M, Seufferlein T, Malek N, Weichert W, Schirmacher P, Penzel R, Endris V, Brors B, Klauschen F, Glimm H, Fröhling S, Stenzinger A.

Int J Cancer. 2019 Dec 1;145(11):2996-3010. doi: 10.1002/ijc.32358. Epub 2019 May 21.

PMID:
31008532
20.

RIPK1 and death receptor signaling drive biliary damage and early liver tumorigenesis in mice with chronic hepatobiliary injury.

Krishna-Subramanian S, Singer S, Armaka M, Banales JM, Holzer K, Schirmacher P, Walczak H, Kollias G, Pasparakis M, Kondylis V.

Cell Death Differ. 2019 Apr 15. doi: 10.1038/s41418-019-0330-9. [Epub ahead of print]

PMID:
30988397
21.

Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome.

Bochtler T, Endris V, Leichsenring J, Reiling A, Neumann O, Volckmar AL, Kirchner M, Allgäuer M, Schirmacher P, Krämer A, Stenzinger A.

Int J Cancer. 2019 Dec 1;145(11):2963-2973. doi: 10.1002/ijc.32316. Epub 2019 Apr 29.

PMID:
30963573
22.

YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells.

Wei T, Weiler SME, Tóth M, Sticht C, Lutz T, Thomann S, De La Torre C, Straub B, Merker S, Ruppert T, Marquardt J, Singer S, Gretz N, Schirmacher P, Breuhahn K.

Oncogene. 2019 Jul;38(27):5541-5550. doi: 10.1038/s41388-019-0801-y. Epub 2019 Apr 1.

PMID:
30936457
23.

RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours.

Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A.

Gut. 2019 Jul;68(7):1287-1296. doi: 10.1136/gutjnl-2018-317632. Epub 2019 Feb 2.

PMID:
30901310
24.

Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p.

Goeppert B, Truckenmueller F, Ori A, Fritz V, Albrecht T, Fraas A, Scherer D, Silos RG, Sticht C, Gretz N, Mehrabi A, Bewerunge-Hudler M, Pusch S, Bermejo JL, Dietrich P, Schirmacher P, Renner M, Roessler S.

Sci Rep. 2019 Mar 18;9(1):4796. doi: 10.1038/s41598-019-40857-3.

25.

Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma.

Goeppert B, Renner M, Singer S, Albrecht T, Zhang Q, Mehrabi A, Pathil A, Springfeld C, Köhler B, Rupp C, Weiss KH, Kühl AA, Arsenic R, Pape UF, Vogel A, Schirmacher P, Roessler S, Utku N.

Sci Rep. 2019 Mar 13;9(1):4338. doi: 10.1038/s41598-019-40487-9.

26.

Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro.

Saborowski A, Wolff K, Spielberg S, Beer B, Hartleben B, Erlangga Z, Becker D, Dow LE, Marhenke S, Woller N, Unger K, Schirmacher P, Manns MP, Marquardt JU, Vogel A, Saborowski M.

Hepatol Commun. 2019 Feb 5;3(3):423-436. doi: 10.1002/hep4.1312. eCollection 2019 Mar.

27.

HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in Germany.

Baretton G, Kreipe HH, Schirmacher P, Gaiser T, Hofheinz R, Berghäuser KH, Koch W, Künzel C, Morris S, Rüschoff J; Nicht-interventionelle Untersuchung (NIU) HER2 Study Group.

Virchows Arch. 2019 May;474(5):551-560. doi: 10.1007/s00428-019-02541-9. Epub 2019 Mar 2.

PMID:
30826877
28.

Emerging Role of the Pathologist in Precision Medicine for HCC.

Longerich T, Schirmacher P.

Dig Dis Sci. 2019 Apr;64(4):928-933. doi: 10.1007/s10620-019-05548-z. Review. No abstract available.

PMID:
30815826
29.

Vascular Biomaterial Banking in Academia.

Hakimi M, Wortmann M, Böckler D, Schirmacher P, Herpel E, Peters AS.

Eur Surg Res. 2019;60(1-2):13-23. doi: 10.1159/000495525. Epub 2019 Feb 6.

PMID:
30726831
30.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E.

Ann Oncol. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510. No abstract available.

PMID:
30715202
31.

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.

Christopoulos P, Dietz S, Kirchner M, Volckmar AL, Endris V, Neumann O, Ogrodnik S, Heussel CP, Herth FJ, Eichhorn M, Meister M, Budczies J, Allgäuer M, Leichsenring J, Zemojtel T, Bischoff H, Schirmacher P, Thomas M, Sültmann H, Stenzinger A.

Cancers (Basel). 2019 Jan 21;11(1). pii: E124. doi: 10.3390/cancers11010124.

32.

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.

Volckmar AL, Leichsenring J, Kirchner M, Christopoulos P, Neumann O, Budczies J, Morais de Oliveira CM, Rempel E, Buchhalter I, Brandt R, Allgäuer M, Talla SB, von Winterfeld M, Herpel E, Goeppert B, Lier A, Winter H, Brummer T, Fröhling S, Faehling M, Fischer JR, Heußel CP, Herth F, Lasitschka F, Schirmacher P, Thomas M, Endris V, Penzel R, Stenzinger A.

Int J Cancer. 2019 Aug 1;145(3):649-661. doi: 10.1002/ijc.32133. Epub 2019 Feb 19.

PMID:
30653256
33.

[Spindle and giant cell type undifferentiated carcinoma of the distal bile duct: a case report].

Albrecht T, Mehrabi A, Strobel O, Vogel MN, Stenzinger A, Bergmann F, Schirmacher P, Goeppert B.

Z Gastroenterol. 2019 Jan;57(1):52-56. doi: 10.1055/a-0784-8763. Epub 2019 Jan 14. Review. German.

PMID:
30641603
34.

Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.

Goeppert B, Toth R, Singer S, Albrecht T, Lipka DB, Lutsik P, Brocks D, Baehr M, Muecke O, Assenov Y, Gu L, Endris V, Stenzinger A, Mehrabi A, Schirmacher P, Plass C, Weichenhan D, Roessler S.

Hepatology. 2019 May;69(5):2091-2106. doi: 10.1002/hep.30493. Epub 2019 Feb 28.

35.

Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression.

Apostolidis L, Pfeiffenberger J, Gotthardt D, Radeleff B, Mehrabi A, Schemmer P, Jäger D, Schirmacher P, Stremmel W, Schulze-Bergkamen H, Springfeld C, Weiss KH.

Gastrointest Tumors. 2018 Sep;5(1-2):38-46. doi: 10.1159/000487635. Epub 2018 Apr 11.

36.

Identification of MALDI Imaging Proteolytic Peptides Using LC-MS/MS-Based Biomarker Discovery Data: A Proof of Concept.

Longuespée R, Ly A, Casadonte R, Schwamborn K, Kazdal D, Zgorzelski C, Bollwein C, Kriegsmann K, Weichert W, Kriegsmann J, Schirmacher P, Fresnais M, Oliveira C, Kriegsmann M.

Proteomics Clin Appl. 2019 Jan;13(1):e1800158. doi: 10.1002/prca.201800158. Epub 2018 Dec 19.

PMID:
30525291
37.

Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.

Budczies J, Seidel A, Christopoulos P, Endris V, Kloor M, Győrffy B, Seliger B, Schirmacher P, Stenzinger A, Denkert C.

Oncoimmunology. 2018 Oct 19;7(12):e1526613. doi: 10.1080/2162402X.2018.1526613. eCollection 2018.

PMID:
30524909
38.

Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.

Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Fröhling S, Penzel R, Thomas M, Schirmacher P, Stenzinger A.

Transl Lung Cancer Res. 2018 Dec;7(6):703-715. doi: 10.21037/tlcr.2018.08.14. Review.

39.

Preoperative Thrombocytopenia May Predict Poor Surgical Outcome after Extended Hepatectomy.

Golriz M, Ghamarnejad O, Khajeh E, Sabagh M, Mieth M, Hoffmann K, Ulrich A, Hackert T, Weiss KH, Schirmacher P, Büchler MW, Mehrabi A.

Can J Gastroenterol Hepatol. 2018 Nov 1;2018:1275720. doi: 10.1155/2018/1275720. eCollection 2018.

40.

Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.

Endris V, Buchhalter I, Allgäuer M, Rempel E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, Neumann O, Penzel R, Weichert W, Glimm H, Fröhling S, Winter H, Herth F, Thomas M, Schirmacher P, Budczies J, Stenzinger A.

Int J Cancer. 2019 May 1;144(9):2303-2312. doi: 10.1002/ijc.32002. Epub 2019 Feb 4.

PMID:
30446996
41.

Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice.

Elßner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, Schmitt N, Kautz N, Breuhahn K, Ismail L, Heide D, Hetzer J, García-Beccaria M, Hövelmeyer N, Waisman A, Urbanik T, Mueller S, Gdynia G, Banales JM, Roessler S, Schirmacher P, Jäger D, Schölch S, Keitel V, Heikenwalder M, Schulze-Bergkamen H, Köhler BC.

Gastroenterology. 2019 Mar;156(4):1190-1205.e14. doi: 10.1053/j.gastro.2018.11.018. Epub 2018 Nov 13.

PMID:
30445013
42.

Site-to-Site Reproducibility and Spatial Resolution in MALDI-MSI of Peptides from Formalin-Fixed Paraffin-Embedded Samples.

Ly A, Longuespée R, Casadonte R, Wandernoth P, Schwamborn K, Bollwein C, Marsching C, Kriegsmann K, Hopf C, Weichert W, Kriegsmann J, Schirmacher P, Kriegsmann M, Deininger SO.

Proteomics Clin Appl. 2019 Jan;13(1):e1800029. doi: 10.1002/prca.201800029. Epub 2019 Jan 4.

43.

BRAF mutation testing in melanoma: results from a German observational multicenter study.

Hartmann A, Schirmacher P, Sterlacci W, Koch W, Liesenfeld DB, Schif B, Garbe C.

Virchows Arch. 2019 Jan;474(1):71-78. doi: 10.1007/s00428-018-2480-4. Epub 2018 Nov 7.

PMID:
30406424
44.

Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.

Goeppert B, Roessler S, Renner M, Singer S, Mehrabi A, Vogel MN, Pathil A, Czink E, Köhler B, Springfeld C, Pfeiffenberger J, Rupp C, Weiss KH, Schirmacher P, von Knebel Doeberitz M, Kloor M.

Br J Cancer. 2019 Jan;120(1):109-114. doi: 10.1038/s41416-018-0199-2. Epub 2018 Oct 31.

PMID:
30377340
45.

Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases.

Leichsenring J, Stögbauer F, Volckmar AL, Buchhalter I, Oliveira C, Kirchner M, Fröhling S, Hassel J, Enk A, Schirmacher P, Endris V, Penzel R, Stenzinger A.

Pathology. 2018 Dec;50(7):703-710. doi: 10.1016/j.pathol.2018.08.004. Epub 2018 Oct 20.

PMID:
30348504
46.

[Centralized molecular tumor diagnostics by commercial providers : Consequences for patients, patient care, and research].

Schirmacher P, Stenzinger A, Kirchner T.

Pathologe. 2018 Nov;39(6):583-586. doi: 10.1007/s00292-018-0523-x. German. No abstract available.

PMID:
30338351
47.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Vogel A, Cervantes A, Chau I, Daniele B, Llovet J, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308. No abstract available.

PMID:
30285213
48.

Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.

Christopoulos P, Kirchner M, Bozorgmehr F, Endris V, Elsayed M, Budczies J, Ristau J, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Lasitschka F, Bischoff H, Sotillo R, Schirmacher P, Thomas M, Stenzinger A.

Int J Cancer. 2019 Jan 1;144(1):190-199. doi: 10.1002/ijc.31893. Epub 2018 Oct 30.

PMID:
30255938
49.

Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis.

Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, Kirchner M, Leichsenring J, Lier A, von Winterfeld M, Penzel R, Christopoulos P, Thomas M, Fröhling S, Schirmacher P, Budczies J, Stenzinger A.

Int J Cancer. 2019 Feb 15;144(4):848-858. doi: 10.1002/ijc.31878. Epub 2018 Dec 4.

PMID:
30238975
50.

Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study.

Volckmar AL, Endris V, Gaida MM, Leichsenring J, Stögbauer F, Allgäuer M, von Winterfeld M, Penzel R, Kirchner M, Brandt R, Neumann O, Sültmann H, Schirmacher P, Rudi J, Schmitz D, Stenzinger A.

Genes Chromosomes Cancer. 2019 Jan;58(1):3-11. doi: 10.1002/gcc.22682. Epub 2018 Oct 17.

PMID:
30230086

Supplemental Content

Loading ...
Support Center